Compounds > razoxane
Page last updated: 2024-08-23

razoxane and Kidney Neoplasms

razoxane has been researched along with Kidney Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anderson, H; Harris, AL; Miller, MP; Price, P; Propper, D; Wells, P; Yap, JT1
Blann, A; Braybrooke, JP; Crew, J; Dobbs, N; Ganesan, TS; Han, C; Harris, AL; Mitchell, K; O'Byrne, KJ; Propper, DJ; Saunders, M; Smith, K; Stephens, R; Talbot, DC; Woodhull, J1
Barleon, B; Dobbs, N; Hang, C; Harris, AL; Marme, D; Reusch, P1
Adamkiewicz-Drozyńska, E; Aleszewicz-Baranowska, J; Balcerska, A; Bień, E; Kaczorowska, B; Kowalczyk, J; Kołecki, P; Kurylak, A; Sierota, D; Stachowicz-Stencel, T; Stefanska, K; Szołkiewicz, A1
Birch, R; Brubaker, LH; Einhorn, LH; Vogel, CL1

Trials

4 trial(s) available for razoxane and Kidney Neoplasms

ArticleYear
Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.
    British journal of cancer, 2003, Jul-21, Volume: 89, Issue:2

    Topics: Antineoplastic Agents; Carbon Monoxide; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neovascularization, Pathologic; Oxygen Radioisotopes; Razoxane; Regional Blood Flow; Tomography, Emission-Computed; Water

2003
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; E-Selectin; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Lymphokines; Male; Middle Aged; Neovascularization, Pathologic; Razoxane; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Time Factors; Topoisomerase II Inhibitors; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; von Willebrand Factor

2000
Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7

    Topics: Antineoplastic Agents; Binding Sites; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins; Razoxane; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Solubility; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2001
Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
    Cancer treatment reports, 1986, Volume: 70, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Piperazines; Razoxane; Stereoisomerism

1986

Other Studies

1 other study(ies) available for razoxane and Kidney Neoplasms

ArticleYear
[Cardiotoxic complications in Wilms' tumour survivors after treatment with anthracyclines].
    Medycyna wieku rozwojowego, 2000, Volume: 4, Issue:1 Suppl 2

    Topics: Adolescent; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Child, Preschool; Drug Therapy, Combination; Echocardiography; Female; Heart; Humans; Infant; Kidney Neoplasms; Male; Razoxane; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Wilms Tumor

2000